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Background: One third of travellers to the poor regions of the (sub)tropics become colonized by
extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). Co-resistance to non-beta-
lactam antibiotics complicates the treatment of potential ESBL-PE infections.
Methods: We analysed co-resistance to non-beta-lactams among travel-acquired ESBL-PE isolates of 90
visitors to the (sub)tropics with respect to major risk factors of colonization: destination, age, travellers'
diarrhoea (TD) and antibiotic (AB) use.
Results: Of the ESBL-PE isolates, 53%, 52%, 73%, and 2% proved co-resistant to ciproﬂoxacin, tobramycin,
co-trimoxazole, and nitrofurantoin, respectively. The rates were similar among those with (TDþ) or
without (TD-) travellers' diarrhoea. Among ﬂuoroquinolone-users vs. AB non-users, the co-resistance
rates for ciproﬂoxacin were 95% versus 37% (p ¼ 0.001), for tobramycin 85% versus 43% (p ¼ 0.005),
co-trimoxazole 85% versus 68% (p ¼ 0.146), and nitrofurantoin 5% versus 2% (p ¼ 0.147). In multivariable
analysis co-resistance to ciproﬂoxacin was associated with increasing age, ﬂuoroquinolone use, and
tobramycin resistance.
Conlusions: While TD predisposes to ESBL-PE non-selectively, antimicrobial use favours strains resistant
to drug taken and, simultaneously, any drug with resistance genetically linked to the drug used. Anti-
biotics taken during travel predispose to ESBL-PE with a high co-resistance rate.
© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
International travel is one of the central means by which
resistant intestinal bacteria spread across the globe [1e5]: a sub-
stantial proportion of travellers get colonized by multiresistant
intestinal bacteria, especially extended-spectrum beta-lactamase-
producing Enterobacteriaceae (ESBL-PE) [6e15]. The risk is partic-
ularly high in regions with poor hygiene and weakly implemented
antimicrobial policy, i.e. South Asia [6e9,11e15] followed by
Southeast Asia, Africa and Latin America. The same regions are
associatedwith increased risk of travellers' diarrhoea (TD) [16,17]. Aision of Infectious Diseases,
S, Finland.
sointu.mero@hus.ﬁ (S. Mero),
ri@hus.ﬁ (T. L€a€averi).
r Ltd. This is an open access articlenumber of studies have shown both TD [8,11e15] and antibiotic use
during travel [11e15] to be independent risk factors for coloniza-
tion by ESBL-PE. Besides ESBL-PE, antibiotic users also tend to ac-
quire ciproﬂoxacin-resistant intestinal bacteria [14]. Likewise, in
placebo-controlled studies of travellers taking mecillinam [18] or
trimethoprim/co-trimoxazole [19], antibiotic users have shown
increased rates of resistant E. coli.
Antimicrobials disrupt the ecological balance of an individual's
own microbiota, thus breaking colonization resistance [20,21]. The
presence of the antibiotic favours growth and colonization by drug-
resistant organisms [20e22] and, occasionally, such bacteria suc-
ceed in causing a clinical infection. As the spread of antimicrobial
resistance across the globe may to a large extent be ascribed to
travellers, understanding the sequelae of their antibiotic use is
especially valuable.
Several studies have shown that ESBL-PE carried by travellersunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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roquinolones (FQs) [6,8e10]. Surprisingly, although co-resistance
further complicates treatment of severe ESBL-PE infections, and
adds to the toll of resistance at hospitals, no studies have thus far
addressed factors determining whether travellers select ESBL-PE
with high or low co-resistance rate. We examined whether the
four major risk factors predisposing to ESBL-PE acquisition (desti-
nation, age, TD and antimicrobial use [6e15]) also contribute to
selecting such co-resistant strains. In addition, we conducted a
multivariable analysis to identify factors associated with/predis-
posing to decreased susceptibility to ciproﬂoxacin, searching tools
for avoiding acquisition of ESBL-PE strains co-resistant to FQ, our
most effective peroral antibiotics for severe ESBL-PE infections.2. Materials and Methods
2.1. Study design, volunteers and samples
To focus on the risk of acquiring ESBL-PE with co-resistance to
non-beta-lactams, we selected among the 430 travellers in our
previous study [11] all the 90 who had contracted ESBL-PE while
abroad. Volunteers had been recruited for the earlier investigation
prospectively over a period of 12 months in 2009e2010; all our 90
ESBL-PE carriers had visited (sub) tropical regions. Each of them
had provided pre- and post-travel stool samples and ﬁlled in two
sets of forms: pre-travel questionnaire covering personal infor-
mation, medical history, and itinerary, and post-travel question-
naire covering symptoms, medications etc. abroad.
The outlines of the current study are presented in Fig. 1. We have
earlier reported ﬁndings of the same cohort with respect to travel-
related health problems [23], travel-acquired ESBL-PE [11], and
various diarrhoeal pathogens [24].
Written informed consent was obtained from all subjects. The
study protocol was approved by the Ethics Committee of the
Department of Medicine in Helsinki University Hospital (406/13/
03/01/08).2.2. Identiﬁcation of ESBL-PE and analysis of co-resistance to
various antibiotics
The identiﬁcation of ESBL-producing strains by phenotypical
and antibiotic resistance is described in detail in our previous study.
In brief, the strains were identiﬁed by the automated VITEK GN
system (bioMerieux, Marcy l'Etoile, France), and the production of
extended-spectrum beta-lactamase by double disk synergy tests
(Oxoid, Thermo Fisher Scientiﬁc, Cambridge, UK). Further suscep-
tibility testing was carried out for various antimicrobials accordingto the criteria of the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) (www.eucast.org), using Muller Hin-
ton agar (Oxoid, Thermo Fisher Scientiﬁc, Cambridge, UK) and
Etests (bioMerieux, Marcy l'Etoile, France; Lioﬁlchem, Roseto Degli
Abruzzi, Italy). The susceptibility results were interpreted as Min-
imum Inhibitory Concentrations (MIC) breakpoints according to
limits recommended by the EUCAST (v 6.0) [25].
For travellers who had contractedmore than one ESBP-PE strain,
the most resistant one was selected (as graded by degree of resis-
tance to ciproﬂoxacin and tobramycin, in this order). Of 98 strains,
90 were eventually selected.
2.3. Analysis of co-resistance with respect to major risk factors
The co-resistance of the ESBL strains was analysed with respect
to the four main risk factors categorized as follows:
Travel destination: (1) South Asia, (2) Southeast Asia, (3) East
Asia, (4) North Africa and the Middle East, (5) Sub-Saharan Africa,
and (6) South and Central America, and the Caribbean.
Age: 0e30, 30e50 and over 50 years of age.
Travellers' diarrhoea: TDþ and TDe groups according to
occurrence of travellers' diarrhoea [7]; TD deﬁned by WHO criteria
as passage of three or more loose or liquid stools per day, or more
frequently than is normal for the individual.
Antibiotic use: ABþ and ABe groups according to antibiotic use
abroad. ABþ group further divided by AB type: (1) FQ users and (2)
users of other antibiotics or regimen not known.
2.4. Analysis of factors associated with FQ resistance
Using a multivariable model, data obtained from questionnaires
concerning travel-related speciﬁcs (itinerary, behaviour, symptoms
andmedication during travel etc.) were studied for associationwith
ciproﬂoxacin resistance.
2.5. Statistics
Statistical analyses were carried out by SPSS software version 22
(IBM Corp, Armonk, NY, USA). The chi-square test, Fisher's exact
test or binary logistic regression analysis were used to compare
categorical variables when applicable, and binary logistic regres-
sion, Mann-Whitney U test, and Kruskall Wallis test were used with
continuous variables when applicable.
Variables with a p-value <0.1 in the univariate analysis for cip-
roﬂoxacin resistance were included in multivariable analyses
together with TD and geographic region, both of which are risk
factors that several studies have found to be linked with ESBL-PE
colonization. We included age and age2 as continuous variables in
the model together with age as a categorical variable for sensitivity
analysis. The ﬁnal model was built by using binary logistic regres-
sion analysis with a stepwise backward selection of variables by
Akaike Information Criteria (AIC).
3. Results
3.1. Description of travellers and travels
The demographics of the 90 volunteers who had contracted
ESBL-PE while travelling are presented in Table 1. Data on ABþ,
ABe, TDþ and TDe groups are provided separately.
3.2. Antibiotic susceptibility of ESBL-PE strains
According toMIC values, most of the ESBL-PE strains were found
resistant or showed decreased sensitivity to ampicillin (100%),
Fig. 1. Flow chart of study protocol. The ESBL-PE isolates were tested for antimicrobial susceptibility. Separate analyses were carried out to identify the inﬂuence of destination, age,
TD (TD þ versus TDe groups) and antibiotic use (ABe group, FQ users, those using other antibiotics/regimen not known) on co-resistance. Finally, multivariable analysis was
conducted to ﬁnd out factors associated with co-resistance to ciproﬂoxacin.
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(96%), ceftriaxone (96%), ceftatzidime (73%), cefepime (88%), cip-
roﬂoxacin (53%), levoﬂoxacin (53%), tobramycin (52%), and co-
trimoxazole (73%), whereas resistance proved uncommon to
nitrofurantoin (2%), ertapenem (2%), meropenem (0%), imipenem
(0%), piperacillin þ tazobactam (4%), tigecyclin (0%), and colistin
(1%).
Resistance to non-beta-lactams ciproﬂoxacin, tobramycin, co-
trimoxazole and nitrofurantoin was subjected to further analyses.
Table 2 shows medians of the MIC values and interpretation of co-
resistance (intermediate or resistant) to these antibiotics.3.3. Association of geographic region, age, TD, and antimicrobial
use with co-resistance among travel-acquired ESBL-PE
In the destination-speciﬁc analysis, strains contracted in South
Asia appeared more sensitive to tobramycin than those originating
in other regions (Table 2). As for sensitivity to other non-beta-
lactams covered, no differences were seen between the various
regions.
Co-resistance of ESBL strains to ciproﬂoxacin and co-
trimoxazole was associated with increasing age; no such differ-
ences were seen for tobramycin or nitrofurantoin (Table 2).
TD was reported by 75/90 (83%) of the subjects. Comparison
between the TDþ and TDe groups revealed no signiﬁcant differ-
ences in co-resistance rates to the antibiotics included in the
analysis (Table 2).
The proportion of ESBL-PE strains resistant to ciproﬂoxacin was
37% among those who had refrained from taking antimicrobials,
but 95% among those who had taken FQwhile abroad (Table 2). The
use of FQ also increased the proportion of ESBL-PE resistant to
tobramycin (85% versus 32%, respectively). The indication for taking
antibiotics was TD in 24/28 cases (86%).
Data on resistance to a given antimicrobial related to resistance
to others are shown in Table 2.3.4. Identiﬁcation of factors associated with co-resistance to
ciproﬂoxacin among travel-acquired ESBL-PE
The univariate analysis (Table 3) detected the following factors
with p < 0.1: (1) tobramycin resistance; (2) co-trimoxazole resis-
tance; (3) age and age group; (4) use of ﬂuoroquinolones; (5) use of
antibiotics other than ﬂuoroquinolones/regimen not known. When
all these were subjected to multivariable analysis together with
geographic region and TD, the following were found to be inde-
pendently associated with co-resistance to ciproﬂoxacin (Table 4):
(1) tobramycin resistance; (2) age group; (3) use of ﬂuo-
roquinolones; (4) use of antibiotics other than ﬂuoroquinolones/
regimen not known. Age explained the outcome better as cate-
gorical than continuous variable. The ﬁt of the model appears
rather good (Nagelkerke R square 0.543), suggesting that the model
predicts outcome values quite well.
4. Discussion
Travellers visiting regions with uncontrolled antibiotic use and
poor hygiene are known to acquire resistant bacteria and carry
them from one geographic region to another [1e15,26]. While
recent data show that destination [6e9,11e15], age [8,11], TD
[7,8,11,13e15] and antibiotic use [11e15] all predispose to coloni-
zation by ESBL-PE, our data reveal that the menace posed by anti-
microbials is even worse. Not only do antibiotic users contract
higher rates of ESBL-PE but, indeed, the acquisition process is se-
lective, favouring strains resistant to, besides many beta-lactams,
also some clinically important non-beta-lactams.
4.1. Co-resistance to non-beta-lactam antibiotics among travel-
acquired ESBL-PE
It is clinically noteworthy that many ESBL-PE strains are co-
resistant to some non-beta-lactams [6e10]. Likewise, our strains
Table 1
Demographics of 90 travellers colonized by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) during journey: data provided separately for those
with TD (TDþ) or asymptomatic (TDe) and those using (ABþ) and not using (ABe) antibiotics.
ESBL(þ)
n (%)
TDþ
n (%)
TDe
n (%)
ABþ
n (%)
ABe
n (%)
Sex
Male 51 (46) 34 (45) 7 (47) 12 (43) 29 (47)
Female 49 (54) 41 (55) 8 (53) 16 (57) 33 (53)
TD
No 15 (17) N/A N/A 0 (0) 15 (24)
Yes 75 (83) N/A N/A 28 (100) 47 (76)
Geographic region
South Asia 28 (31) 25 (33) 3 (20) 8 (29) 20 (32)
Southeast Asia 33 (37) 30 (40) 3 (20) 9 (32) 24 (39)
East Asia 2 (2) 2 (3) 0 (0) 2 (7) 0 (0)
North Africa and the Middle East 4 (4) 2 (3) 2 (14) 1 (4) 3 (5)
Sub Saharan Africa 23 (26) 16 (21) 7 (47) 8 (29) 15 (24)
South America, Central America and the Caribbean 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Europe, Australia, and North America 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Length of journey
Days, median 16.5
(IQR 15.0)
19
(IQR 16.0)
13
(IQR 11.0)
21
(IQR 15.3)
16
(IQR 12.3)
Age
Years, median 36.5
(IQR 30.0)
33
(IQR 23.0)
58
(IQR 20.0)
32
(IQR 31.0)
41
(IQR 29.5)
Total 90 (100) 75 (83) 15 (17) 28 (31) 62 (69)
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tobramycin and co-trimoxazole, respectively. The low degree of
resistance to nitrofurantoin (2% in our study) is relevant to treat-
ment, for this drug presents a peroral alternative in uncomplicated
cystitis. Practically all strains were found sensitive to carbapenems,
drugs commonly used as ﬁrst-line intravenous alternatives in se-
vere ESBL infections.
4.2. Effect of geographic region, age and TD on co-resistance among
travel-acquired ESBL-PE strains
Our data did not reveal major differences in the antibiotic
resistance proﬁles between the various destinations, which may
reﬂect, besides high antibiotic pressure in all of them, also the li-
ability of ESBL-PE clones to spread from one region to others, and,
in some cases, even across the globe [1,2].
Our ﬁnding that older age is associated with risk of acquiring co-
trimoxazole- and ciproﬂoxacin-resistant ESBL-PE was unexpected,
and we can only speculate about the reasons. In previous reports,
increasing age has been found to be a risk factor for contracting
ESBL-PE [8,11].
The resistance proﬁles of the ESBL-PE strains did not differ be-
tween the TDþ and TDe groups. The underlying mechanisms in TD
thus appear to be non-selective: disturbance in the microbiota [27]
makes space for all new bacteria alike. The only difference to those
with no TD is a higher load of newcomers, as suggested by the
increased rate of ESBL-PE acquisition. Therefore the selection of
ESBL-PE among these two groups can be presumed to reﬂect the
general proﬁle of the ESBL-PE to which travellers are exposed in
their destinations (Fig. 2).
4.3. Effect of antimicrobial use on co-resistance among travel-
acquired ESBL-PE strains
The main ﬁnding of the present study is that among antibiotic
users the process of ESBL-PE acquisition is selective, favouring
strains resistant to the drug taken (Fig. 2, Table 4). We discovered
that while 37% of the ESBL-PE strains contracted by travellers who
had not used antibiotics were ciproﬂoxacin-resistant, among FQ-
users the rate was as high as 95%. This seems logical, for eachantimicrobial is expected not only to kill bacteria sensitive to that
drug but e at the same time e also open a niche in the intestinal
microbiota for strains resistant to it [20,21,28].
Virtually all ESBL bacteria in the group using FQs were co-
resistant to ciproﬂoxacin. This demonstrates the enormous
impact of antibiotic pressure and selection in the intestine after the
susceptible bacteria have been killed by the antibiotic. In fact, as
reported also by a recent study by Reuland et al. [14], besides ESBLs,
antibiotic users also acquire ciproﬂoxacin-resistant gram-negative
rods. Likewise, in placebo-controlled studies of travellers taking
mecillinam [18] or trimethoprim/co-trimoxazole [19], antibiotic
users had increased rates of E. coli resistant to the drug taken; no
such increase was seen when these drugs were taken by travellers
to other than high risk regions [29,30]. Indeed, in our study, FQ use
probably favoured any ciproﬂoxacin-resistant strains, yet, as only
ESBL-PE was measured, we found an increase in ESBL-PE co-resis-
tant to ciproﬂoxacin. It is noteworthy that, as ESBL bacteria have co-
resistance to numerous other antimicrobials, using any of thosewill
probably further increase the risk of contracting ESBL-PE.4.4. Impact of genetic linkage between resistance to various
antibiotics
Another interesting aspect is the genetic linkage between
certain resistance genes: the plasmid harbouring the bla-CTX-M
gene, for example, may carry also FQ resistance genes, and genes
encoding AmpC beta-lactamases (plasmid blaAmpC) and carbape-
nemases or enzymes inactivating aminoglycosides [31]. Due to the
co-selection process, the presence of any of these antibiotics would
give advantage to blaCTX-M [31]. In addition to common topo-
isomerase gene point-mutations and active efﬂux pumps, nor-
ﬂoxacin and ciproﬂoxacin resistance may be linked with
aminoglycoside resistance owing to the plasmid-mediated resis-
tance gene aac(60)-Ib-cr which confers resistance to both antibiotic
groups [32]. Depending on sequence type and plasmid proﬁle,
strains may also confer resistance to tetracycline, nalidixic acid,
chloramphenicol, trimethoprim, and sulfonamides [33,34]. In
accord with the genetic link between FQ and tobramycin resistance,
tobramycin co-resistance was more frequent among ESBL-PE con-
tracted by those who had taken ciproﬂoxacin during travel than
Table 2
Relation between co-resistance among travel-acquired ESBL-PE and geographic region visited, age group, TD, use of antimicrobials (AB) and simultaneous co-resistance to
ciproﬂoxacin, tobramycin, co-trimoxazole and nitrofurantoin. For antimicrobial use, data are shown separately for those not having used antibiotics (ABe), those having taken
ﬂuoroquinolones, and those having used other antibiotics/whose regimen was not known. MICs are given as medians of values. Each strain was interpreted as resistant (R) or
intermediate (I) according to MICs using EUCAST clinical breakpoints. All strains were Escherichia coli, apart from one Klebsiella pneumoniae and one E. hermannii.
Total Ciproﬂoxacin Tobramycin Co-trimoxazole Nitrofurantoin
n (%) MIC
(mg/l)
(R þ I)
n (%)
OR
(95% CI)
p-value MIC
(mg/l)
(R þ I)
n (%)
OR
(95% CI)
p-value MIC
(mg/l)
(R þ I)
n (%)
OR
(95% CI)
p-value MIC
(mg/l)
(R þ I)
n (%)
OR
(95% CI)
p-value
Geographic region
South Asia 28 (31) 0.44 13 (46) 1.0 <1 7 (25) 1.0 >32 18 (64) 1.0 12 0 (0) 1.0
South East Asia 33 (37) 2 17 (52) 1.2
(0.4e3.3)
0.692 3 22 (67) 6.0
(2.0e18.4)
0.002 >32 26 (79) 2.1
(0.7e6.4)
0.212 8 3 (9) 0.8
(0.1e14.1)
0.906
East Asia 2 (2) >32 2 (100) N/A N/A 5 2 (100) N/A N/A >32 2 (100) N/A 0.999 16 0 (0) N/A 0.999
North Africa and
Middle East
4 (4) 0.014 1 (25) 0.4
(0.0e4.2)
0.432 <1 1 (25) 1.0
(0.1e11.2)
1.000 16 2 (50) 0.6
(0.1e4.6)
0.585 12 0 (0) N/A 0.999
SubeSaharan Africa 23 (26) >32 15 (65) 2.2
(0.7e6.7)
0.183 6 15 (65) 5.6
(1.7e18.9)
0.005 >32 18 (78) 2.0
(0.6e7.0)
0.280 8 1 (4) N/A 0.998
p-value for MIC
(geographic
region)
0.172 0.118 0.414 0.196
Age group
0e30 29 (32) 0.25 10 (34) 1.0 2 14 (48) 1.0 >32 23 (55) 1.0 12 2 (7) 1.0
31e50 33 (37) >32 18 (55) 2.3
(0.8e6.4)
0.116 3 18 (55) 1.3
(0.5e3.5)
0.622 >32 27 (82) 3.7
(1.2e11.5)
0.027 8 0 (0) N/A 0.998
over 50 28 (31) >32 20 (71) 4.8
(1.5e14.6)
0.006 3 15 (54) 1.2
(0.2e3.5)
0.689 >32 23 (82) 3.7
(1.1e12.6)
0.033 12 0 (0) N/A 0.998
p-value for MIC
(age group)
0.059 0.778 0.056 0.291
TD
No TD 15 (17) 0.38 7 (47) 1.0 1 6 (43) 1.0 >32 9 (60) 1.0 12 0 (0) 1.0
TD 75 (83) 32 41 (55) 1.4
(0.5e4.2)
0.572 3 41 (55) 1.6
(0.5e5.1)
0.416 >32 57 (76) 2.1
(0.7e6.7)
0.207 12 2 (3) 1.0
(1.0e1.1)
0.522
p-value for
MIC (TD)
0.198 0.332 0.195 0.830
Use of antimicrobials
No use of
antimicrobials
60 (69) 0.38 23 (37) 1.0 1 26 (43) 1.0 >32 42 (68) 1.0 12 1 (2) 1.0
Use of
ﬂuoroquinolonesa
21 (23) >32 19 (95) 32.2
(4.0e256.8)
0.001 7 17 (85) 5.5
(1.7e18.3)
0.005 >32 17 (85) 2.7
(0.7e10.3)
0.146 8 1 (5) 3.2
(0.2e53.8)
0.417
Use of antimicrobial
other than
FQ/regimen
not knownb
7 (8) >32 6 (75) 5.1
(0.9e27.3)
0.058 3 4 (50) 1.0
(0.2e4.7)
0.972 >32 7 (88) 3.3
(0.4e29.0)
0.275 N/A 0 (0) N/A N/A
p-value for MIC
(use of AB)
<0.001 0.002 0.184 0.011
Co-resistance to other antimicrobials
Ciproﬂoxacin 48 (53) e e e e 6 35 (73) 6.7
(2.7e17.0)
<0.001 >32 42 (88) 5.3
(1.8e15.0)
0.002 8 1 (2) 0.9
(0.1e14.4)
1.000
Tobramycin 47 (52) 32 35 (75) 6.7
(2.7e17.0)
<0.001 e e e e >32 41 (87) 4.9
(1.7e14.1)
0.002 8 2 (4) N/A 0.495
Co-trimoxazole 66 (73) 32 42 (64) 5.3
(1.8e15.0)
0.002 3 41 (62) 4.9
(1.7e14.1)
0.002 e e e e 1 (2) 0.4
(0.0e5.9)
0.464
Nitrofurantoin 2 (2) N/A 1 (50) 0.9
(0.1e14.4)
1.000 N/A 2 (100) N/A 0.495 N/A 1 (2) 0.4
(0.0e5.9)
0.464 e e e e
Total 90 6 48 (53) 3 47 (52) >32 66 (73) 12 4 (4)
a In addition to FQ, one subject took also ceftriaxone, one amoxixillin-clavulanic acid, and one nitroimidazole plus roxithromycin.
b Three took azithromycin, one amoxicillin-clavulanic acid; in three cases the regimen was unknown.
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furantoin and co-trimoxazole resistance rates were not signiﬁ-
cantly inﬂuenced by antimicrobial use, presumably because of their
resistance mechanism not being linked to ciproﬂoxacin resistance
genes for instance in the same success clones with typical mobile
elements. In principle one could, therefore, to a certain degree
predict the types of potential resistance problems by the antimi-
crobial taken.4.5. Scenery of impact of antibiotic use
Taken together, antibiotics appear to play three vicious tricks ontravellers. Firstly, they disrupt intestinal colonization resistance and
make space for newcomers; secondly, they only favour colonization
by bacteria resistant to the antibiotic taken; and last but not least,
resistant bacteria tending to be co-resistant to other antibiotics,
users end up selecting the most resistant bacteria from the sur-
roundings (Fig. 2). Besides adding to the vast body of research
reporting an increased risk for travellers to contract ESBL-PE
[6e15,26], the present data reveal that the strains acquired are
not just any ESBL-PE but those with the highest co-resistance rates:
in FQ users the selection favours co-resistance to FQs and tobra-
mycin, both drugs used for severe infections and thus of great
clinical importance.
Table 3
Factors associated with colonization by ciproﬂoxacin-resistant ESBL-PE strains: results of univariate analysis.
Risk factors All (n ¼ 90)
n (%)
Ciproﬂoxacin I þ R
n (%)
Univariate OR
(95% CI)
p in univariate
analysis
Decreased susceptibility or resistance to non-beta-lactams
Nitrofurantoin I þ R 2 (2) 1(50) 0.9 (0.1e14.4) 1.000
Tobramycin I þ Ra 47 (52) 35 (75) 6.7 (2.7e17.0) <0.001
Co-trimoxazole I þ Ra 66 (73) 42 (64) 5.3 (1.8e15.0) 0.002
Sex
Male 41 (46) 18 (44) 1.0 N/A
Female 49 (54) 30 (61) 2.0 (0.9e4.7) 0.101
Agea, years, median, IQR 36.5 (IQR 30)
(range 11e77)
47 (IQR 29.5)
(range 24e77)
1.0 (1.0e1.1) 0.007
Age groupa 0.020
0e30 29 (32) 10 (34) 1.0 N/A
31e50 33 (37) 18 (55) 2.3 (0.8e6.4) 0.116
Over 50 28 (31) 20 (71) 4.8 (1.5e14.6) 0.006
Geographic regiona 0.295
South Asia 28 (31) 13 (46) 1.0 N/A
Southeast Asia 33 (37) 17 (52) 1.2 (0.4e3.3) 0.692
East Asia 2 (2) 2 (100) N/A N/A
North Africa and the Middle East 4 (4) 1 (25) 0.4 (0.0e4.2) 0.432
Sub Saharan Africa 23 (26) 15 (65) 2.2 (0.7e6.7) 0.183
South America, Central America and the Caribbean 0 (0) 0 N/A N/A
North America, Europe, Australia 0 (0) 0 N/A N/A
Length of journey
Days, median 16.5 (IQR 15)
(range 5e133)
17.5 (IQR 15.5)
(range 5e133)
1.0 (1.0e1.0) 0.679
Group 0.177
2 weeks or less 33 (37) 15 (46) 1.0 N/A
2 weeks1 month 42 (47) 26 (62) 2.0 (0.8e4.9) 0.157
Over 1 month 15 (47) 7 (47) 0.9 (0.3e3.5) 0.938
TDa
No TD 15 (17) 7 (47) 1.0 N/A
TD 75 (83) 41 (55) 1.4 (0.5e4.2) 0.572
Use of loperamide 28 (31) 13 (46) 0.7 (0.3e1.6) 0.378
Use of antimicrobial medicationsa
None 62 (69) 23 (37) 1.0
FQ (vs noAB) 20 (22) 19 (95) 32.2 (4.0e256.8) 0.001
other/regimen unknown (vs no AB) 8 (9) 6 (75) 5.1 (0.9e27.3) 0.058
Other factors
Use of alcohol: 3 or more vs. 0e2 units/day (information missing 8) 16 (20) 10 (63) 1.6 (0.5e4.8) 0.429
Meals with locals (information missing 3) 7 (8) 3 (43) 0.6 (0.1e2.9) 0.536
Site of meals: restaurant>50% vs. mainly at own household (information missing 1) 82 (92) 45 (55) 1.6 (0.3e7.7) 0.540
Contact with local healthcare 15 (17) 10 (67) 1.9 (0.6e6.2) 0.257
Accommodation hotel/guesthouse vs. with locals/own household (information missing 3) 80 (92) 43 (54) 1.6 (0.3e7.4) 0.580
Use of probiotics 51 (57) 29 (57) 1.4 (0.6e3.2) 0.443
Use of bottled water 86 (96) 46 (54) 1.2 (0.2e8.5) 0.891
Uncooked meat or ﬁsh 12 (13) 6 (50) 0.8 (0.2e2.9) 0.731
Neglecting hand-washing (information missing 1) 10 (11) 5 (50) 0.9 (0.2e3.3) 0.850
Eating salads (information missing 5) 64 (75) 36 (56) 1.4 (0.5e3.8) 0.491
Chronic illness 22 (24) 13 (59) 1.4 (0.5e3.6) 0.533
Antimalarial chemoprophylaxis 48 (53) 25 (52) 0.9 (0.4e2.1) 0.799
a Included in multivariable analysis (see Table 4).
Table 4
Factors associated with colonization by ﬂuoroquinolone-resistant ESBL-PE strains in ﬁnal multivariable model after backward selection of factors by AIC. Backward selection
eliminated the following factors: decreased sensitivity to co-trimoxazole, TD, age as a continuous variable and geographic region. Values are presented for proportions with a
given risk factor, adjusted odds ratios (AOR), and p-values in multivariable analysis.
Risk factors All (n ¼ 90)
n (%)
Ciproﬂoxacin
I þ R
OR
(95% CI)
p in univariate
analysis
AOR
(95% CI)
p in multivariable
analysis
Decreased susceptibility or resistance to non-beta-lactams
Tobramycin R þ I 47 (52) 35 (75) 6.7 (2.7e17.0) <0.001 5.4 (1.7e17.0) 0.004
Age group
0e30 29 (32) 10 (34) 1.0 N/A 1.0 N/A
31e50 33 (37) 18 (55) 2.3 (0.8e6.4) 0.116 4.9 (1.1e23.1) 0.430
Over 50 28 (31) 20 (71) 4.8 (1.5e14.6) 0.006 14.0 (2.7e71.5) 0.002
Use of antimicrobial medications
None 62 (69) 23 (37) 1.0 N/A 1.0 N/A
FQ (vs noAB) 20 (22) 19 (95) 32.2 (4.0e256.8) 0.001 41.8 (4.0e436.3) 0.002
Other/regimen unknown (vs no AB) 8 (9) 6 (75) 5.1 (0.9e27.3) 0.058 8.4 (1.2e59.1) 0.032
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Fig. 2. Hypothetical model of the inﬂuence of destination, diarrhoea (D)/travellers'
diarrhoea (TD) and antibiotic (AB) use on acquisition of multidrug-resistant (MDR)
intestinal bacteria. Size of circle corresponds to relative risk of acquisition. Interpre-
tation: MDR bacteria can only be contracted in an environment where they are
prevalent (low-versus high-risk regions). Diarrhoea predisposes to bacterial acquisi-
tion unselectively: higher loads are contracted by those with than those without D/TD,
yet the MDR proportion equals that in the surroundings. ABs predispose to bacterial
acquisition selectively: (1) users not only contract MDR in greater proportions than
present in the surroundings, but (2) they select those MDR which are co-resistant to
the AB they used e and possibly even resistance to ABs genetically linked to that
particular drug. AB users thus end up selecting MDR bacteria with the highest co-
resistance rates.
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To explore further the clinically relevant FQ resistance, we
searched for factors associated with colonization by ciproﬂoxacin-
resistant strains among ESBL-PE. A recent study identiﬁed two in-
dependent risk factors predisposing to ciproﬂoxacin-resistant
strains: travel to Asia, and combination of TD and antibiotic use
[14]. Our analysis showed FQ use, use of other antimicrobials,
tobramycin resistance, and age to be linked with co-resistance to
ciproﬂoxacin among ESBL-PE. Interestingly, TDwas not a signiﬁcant
risk factor for ciproﬂoxacin co-resistance. This ﬁnding accords with
the discussion above, where TD is considered to predispose trav-
ellers to resistant intestinal bacteria in the surroundings non-
selectively, without favouring FQ-resistant strains.
4.7. Limitations
Although our statistical analyses showed that the use of “other
antibiotics/regimen not known” predisposes to selecting
ciproﬂoxacin-resistant ESBL-PE, we do not regard this result as
quite reliable, with the number of cases being only seven and the
antibiotic regimen not known in three of them, meaning that it
could have been a FQ.
It would have been of interest also to examine the resistance
proﬁles of some other intestinal bacteria, but we only had the ESBL-
PE available. On the other hand, it appears reasonable to consider
ESBL-PE here as a model, and our ﬁndings thus applicable to other
intestinal gram-negative bacteria.
4.8. Practical points
We recently concluded that to prevent ESBL-PE colonization,
travellers should be advised to prevention of TD and avoiding un-
necessary antimicrobials [11,35]. The current results highlight the
very same point: to prevent travellers from contracting the most
resistant ESBL, i.e. those with co-resistance to clinically important
non-beta-lactams, when giving pre-travel advice, particular effort
should be put into educating travellers to caution in treating TDwith antibiotics. Since mild and moderate TD are typically charac-
terized by spontaneous recovery [17], antibiotics should be
reserved for severe disease only. In mild/moderate cases where
medication is needed, antisecretory/antimotility regimens can be
used: our recent systematic review on loperamide found no proof
of it being less effective than antibiotic treatment [36]. Further-
more, loperamide is safe [36], and when taken singly, does not
increase the risk of colonization by ESBL-PE [37].
If hospitalized at home, returning travellers having treated TD
with antimicrobials while abroad should be considered risk pa-
tients: co-resistance to non-beta-lactams among ESBL strains leads
to increased use of carbapenems, further adding to selection
pressure at hospitals. Practically all our FQ users had ESBL-PE co-
resistant to ciproﬂoxacin, which indicates that ﬂuoroquinolones
should not be used as empiric treatment (in urinary tract infection,
for example) for returning travellers who have used these drugs
when visiting high-risk regions.
4.9. Conclusions
Researching into the effect of TD and antibiotic use on the
acquisition of ESBL-PE while abroad, we found TD to predispose
travellers unselectively to any ESBL-PE, while FQ proved to pre-
dispose both to strains co-resistant to the antibiotic used and those
genetically linked to FQ-resistance. Thus, use of FQs predisposes not
only to contracting ESBL-PE strains but, indeed, also to selecting
ESBL-PE strains co-resistant to certain clinically important non-
beta-lactam antibiotics. The data reveal that the perils of anti-
biotic use during travel are even greater than hitherto recognized.
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